Théroux, Pierre.
Pierre Theroux researcher
VIAF ID: 106549696 (Personal)
Permalink: http://viaf.org/viaf/106549696
Preferred Forms
- 100 0 _ ‡a Pierre Theroux ‡c researcher
-
- 100 1 0 ‡a Théroux, Pierre
-
-
- 100 1 _ ‡a Théroux, Pierre
-
- 100 1 _ ‡a Théroux, Pierre
-
-
- 100 1 _ ‡a Théroux, Pierre
-
-
-
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice G | |
Acute coronary syndromes | |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation | |
Additive Effects of Obesity and TCF7L2 Variants on Risk for Type 2 Diabetes Among Cardiac Patients | |
Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin | |
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. | |
Efficacy and safety of vorapaxar as approved for clinical use in the United States | |
Epidemiologia, patogeneza, rozpoznanie i stratyfikacja | |
Genetic predictors of depressive symptoms in cardiac patients | |
Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library | |
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial | |
Long-term use of ticagrelor in patients with prior myocardial infarction | |
Nifedipine in clinical practice : proceedings of the First International Canadian Nifedipine Symposium, February 11 and 12, 1982, Montreal, Quebec, Canada | |
Ostre zespoły wieńcowe : a companion to Braunwald's heart disease. | |
Patofizjologia choroby wieńcowej | |
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial | |
Platelet function and monitoring with long-term inhibition of the glycoprotein IIb/IIIa receptor with oral antagonists | |
Postępowanie w ostrych zespołach wieńcowych, podstawy rozwoju nowoczesnych oddziałów kardiologicznych i wytyczne postępowania | |
Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. | |
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy | |
Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). | |
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease | |
Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). | |
Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction. | |
Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). | |
Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial | |
Vorapaxar in the secondary prevention of atherothrombotic events |